Neuroprotectants in stroke therapy

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 6, 2008, Pages 887-900

  Jeyaseelan, K ^a   Lim, K Y ^a   Armugam, A ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Antagonist; Cell death; Cerebral ischemia; Clinical trials; Free radical; Infarct size; Neuronal; Neuroprotectant; Stroke

Indexed keywords

3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; [1,2,3,4 TETRAHYDRO 7 (1H IMIDAZOL 1 YL) 6 NITRO 2,3 DIOXO 1 QUINOXALINYL]ACETIC ACID; ALTEPLASE; AMPA RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOPTOSIS INHIBITOR; ARGATROBAN; ARUNDIC ACID; CALCIUM ANTAGONIST; CITICOLINE; CLOMETHIAZOLE; DIAZEPAM; DISUFENTON SODIUM; EBSELEN; GLUTAMATE RECEPTOR ANTAGONIST; HARMOSIKANE; HUMAN ALBUMIN; MAGNESIUM SULFATE; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; NORPHENAZONE; OPIATE ANTAGONIST; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TIRILAZAD; TRAXOPRODIL; UNINDEXED DRUG;

BLOOD PRESSURE; BRAIN EMBOLISM; BRAIN INJURY; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HYPOTHERMIA; LIPID STORAGE; MORBIDITY; MORTALITY; NEUROPROTECTION; NEUROSURGERY; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; OUTCOME ASSESSMENT; PULSE RATE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; EXCITATORY AMINO ACID ANTAGONISTS; GABA AGONISTS; HUMANS; HYPOTHERMIA, INDUCED; ION CHANNEL GATING; ION CHANNELS; MAGNESIUM COMPOUNDS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; RECEPTORS, OPIOID; STROKE;

EID: 42649102049     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.6.887     Document Type: Review

References (100)

1. World Health Report - 2007, from the World Health Organization. International Cardiovascular Disease Statistics (2007 Update), a publication from the American Heart Association.
2. Shearman AM, Cooper JA, Kotwinski PJ, et al. Estrogen receptor alpha gene variation and the risk of stroke. Stroke 2005;36(10):2281-2
3. Albers GW, Caplan LR, Easton JD, et al. Transient ischemic attack - proposal for a new definition. N Engl J Med 2002;347(21):1713-6
4. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003;4(5):399-415
5. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115(5):e69-171
6. McNeil JM, Binette J. Prevalence of disabilities and associated health conditions among adults - United States, 1999. MMWR Morb Mortal Wkly Rep 2001;50(7):120-5
7. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113(6):e85-151
8. Thom T. Incidence and prevalence: chart book on cardiovascular and lung diseases. Bethesda, MD: National Heart, Lung, and Blood Institute (2006)
9. Lyden PD, Shuaib A, Lees KR, et al. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage. The CHANT Trial Stroke 2007;38(8):2262-69
10. Anderson CS, Chakera TM, Stewart-Wynne EG, Jamrozik KD. Spectrum of primary intracerebral haemorrhage in Perth, Western Australia, 1989-90: incidence and outcome. J Neurol Neurosurg Psychiatry 1994;57(8):936-40
11. Pavlakis SG, Sacco R, Levine SR, et al. Lessons from adult stroke trials. Pediatr Neurol 2006;34(6):446-9
12. Kidwell CS, Liebeskind DS, Starkman S, Saver JL. Trends in acute ischemic stroke trials through the 20th century. Stroke 2001;32(6):1349-59
13. Bambauer KZ, Johnston SC, Bambauer DE, Zivin JA. Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol 2006;63(5):661-4
14. Blanco M, Nombela F, Castellanos M, et al. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 2007;69(9):904-10
15. The National Institute of Neurological Disorders and Stroke RT-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333(24):1581-7
16. Sandercock PAG and International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349(9065):1569-81
17. Flint AC, Duckwiler GR, Budzik RF, et al. Mechanical thrombectomy of intracranial internal carotid occlusion: pooled results of the MERCI and Multi MERCI Part I trials. Stroke 2007;38(4):1274-80
18. Health Topics A-Z: Stroke. Available from: http://www.healthywomen.org/ healthtopics/stroke/treatment
19. Hilgartner M, Aledort L, Andes A, Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group. Transfusion 1990;30(7):626-30
20. Aledort L. Inhibitors in hemophilia patients: current status and management. Am J Hematol 1994;47(3):208-17
21. Negrier C, Goudemand J, Sultan Y, et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Thromb Haemost 1997;77(6):1113-9
22. Subarachnoid Hemorrhage. Available from: http://www.emedicine.com/med/ topic2883.htm
23. Erythropoietin Therapy for Subarachnoid Hemorrhage. Available from: http://www.strokecenter.org/trials/TrialDetail.aspx?tid=511
24. Markus R, Reutens DC, Kazui S, et al. Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival. Brain 2004;127(Pt 6):1427-36
25. Labiche LA, Grotta JC. Clinical trials for cytoprotection in stroke. NeuroRx 2004;1(1):46-70
26. Cheng YD, Al-Khoury L, Zivin JA, Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004;1(1):36-45
27. Oka M, Itoh Y, Ukai Y. Preferential inhibition by a novel Na(+)/Ca(2+) channel blocker NS-7 of severe to mild hypoxic injury in rat cerebrocortical slices: a possible involvement of a highly voltage-dependent blockade of Ca(2+) channel. J Pharmacol Exp Ther 2000;293(2):522-9
28. 2+ channel blocker, prevents neurologic injury after spinal cord ischemia in rabbits. J Thorac Cardiovasc Surg 2005;129(2):364-71
29. Gribkoff VK, Starrett JE Jr, Dworetzky SI, et al. Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat Med 2001;7(4):471-7
30. Stroke Trials Registry. Available from: http://www.strokecenter.org/ trials
31. Guyot LL, Diaz FG, O'Regan MH, et al. Real-time measurement of glutamate release from the ischemic penumbra of the rat cerebral cortex using a focal middle cerebral artery occlusion model. Neurosci Lett 2001;299(1/ 2):37-40
32. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995;26(3):503-13
33. Bullock MR, Merchant RE, Carmack CA, et al. An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage. Ann NY Acad Sci 1999;890:51-8
34. Merchant RE, Bullock MR, Carmack CA, et al. A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury Ann NY Acad Sci 1999;890:42-50
35. Kawasaki-Yatsugi S, Yatsugi S, Takahashi M, et al. A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats. Brain Res 1998;793(1/2):39-46
36. Shimizu-Sasamata M, Kano T, Rogowska J, et al. YM872, a highly water-soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats. Stroke 1998;29(10):2141-8
37. Kawasaki-Yatsugi S, Ichiki C, Yatsugi S, et al. Neuroprotective effects of an AMPA receptor antagonist YM872 in a rat transient middle cerebral artery occlusion model. Neuropharmacology 2000;39(2):211-7
38. Muir KW. Magnesium in stroke treatment. Postgrad Med J 2002;78(925):641-5
39. 2+ in cultured cortical neurons. Neuron 1993;11(4):751-7
40. Chi OZ, Pollak P, Weiss HR. Effects of magnesium sulfate and nifedipine on regional cerebral blood flow during middle cerebral artery ligation in the rat. Arch Int Pharmacodyn Ther 1990;304:196-205
41. Marinov MB, Harbaugh KS, Hoopes PJ, et al. Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg 1996;85(1):117-24
42. Yang Y, Li Q, Ahmad F, Shuaib A. Survival and histological evaluation of therapeutic window of post-ischemia treatment with magnesium sulfate in embolic stroke model of rat. Neurosci Lett 2000;285(2):119-22
43. Muir KW, Lees KR. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke 1995;26(7):1183-8
44. Muir KW, Lees KR, Ford I, Davis S. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke Trial): randomised controlled trial. Lancet 2004;363(9407):439-45
45. Cao W, Carney JM, Duchon A, et al. Oxygen free radical involvement in ischemia and reperfusion injury to brain. Neurosci Lett 1988;88(2):233-8
46. Clark WM, Hazel JS, Coull BM. Lazaroids. CNS pharmacology and current research. Drugs 1995;50(6):971-83
47. Sugawara T, Chan PH. Reactive oxygen radicals and pathogenesis of neuronal death after cerebral ischemia. Antioxid Redox Signal 2003;5(5):597-607
48. Hall ED. Inhibition of lipid peroxidation in central nervous system trauma and ischemia. J Neurol Sci 1995;134(Suppl):79-83
49. Lapchak PA, Chapman DF, Zivin JA. Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 2001;32(1):147-53
50. Tirilazad International Steering Committee. Tirilazad mesylate in acute ischemic stroke: a systematic review. Stroke 2000;31(9):2257-65
51. Venti M, Parnetti L, Silvestrelli G, Gallai V. Role of neuroprotective drugs in acute ischemic stroke. Cerebrovasc Dis 2000;10(Suppl 4):24-6
52. Zhao Z, Cheng M, Maples KR, et al. NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat. Brain Res 2001;909(1/2):46-50
53. Sydserff SG, Borelli AR, Green AR, Cross AJ. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 2002;135(1):103-12
54. Marshall JW, Duffin KJ, Green AR, Ridley RM. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001;32(1):190-8
55. Sydserff SG, Borelli AR, Green AR, Cross AJ. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 2002;135(1):103-12
56. Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006;354(6):588-600
57. Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007;357(6):562-71
58. AstraZeneca Announces SAINT II Trial Results Showed No Efficacy in Acute Ischaemic Stroke. Available from: http://www.astrazeneca.com/ pressrelease/5279.aspx
59. Jin YJ, Mima T, Raicu V, et al. Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. Neurosci Res 2002;43(1):75-9
60. Nakamura T, Kuroda Y, Yamashita S, et al. Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. Stroke 2008;39(2):463-9
61. Toyoda K, Fujii K, Kamouchi M, et al. Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. J Neurol Sci 2004;221(1/2):11-7
62. The Edaravone Acute Brain Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003;15(3):222-9
63. Higashi Y, Jitsuikia D, Chayamab K, Yoshizumia M. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a novel free radical scavenger, for treatment of cardiovascular diseases. Recent Patents Cardiovasc Drug Discovery 2006;1:85-93
64. Namba S, Nishigaki S, Fujiwara N, et al. Opiate-antagonist reversal of neurological deficits - experimental and clinical studies. Jpn J Psychiatry Neurol 1986;40(1):61-79
65. Graham SH, Shimizu H, Newman A, et al. Opioid receptor antagonist nalmefene stereospecifically inhibits glutamate release during global cerebral ischemia. Brain Res 1993;632(1/2):346-50
66. Clark WM, Raps EC, Tong DC, Kelly RE. Cervene (nalmefene) in acute ischemic stroke: final results of a Phase III efficacy study. The Cervene Stroke Study Investigators. Stroke 2000;31(6):1234-9
67. Green AR, Hainsworth AH, Jackson DM. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology 2000;39(9):1483-94
68. Moody EJ, Skolnick P. Chlormethiazole: neurochemical actions at the gamma-aminobutyric acid receptor complex. Eur J Pharmacol 1989;164(1):153-8
69. Cross AJ, Jones JA, Baldwin HA, Green AR. Neuroprotective activity of chlormethiazole following transient forebrain ischaemia in the gerbil. Br J Pharmacol 1991;104(2):406-11
70. Lyden P, Shuaib A, Ng K, et al. Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results. Stroke 2002;33(1):122-8
71. Lodder J, Luijckx G, Van Raak L, Kessels F. Diazepam treatment to increase the cerebral GABAergic activity in acute stroke: a feasibility study in 104 patients. Cerebrovasc Dis 2000;10(6):437-40
72. Lodder J, Van Raak L, Hilton A, et al. Diazepam to improve acute stroke outcome: results of the early GABA-Ergic activation study in stroke trial. A randomized double-blind placebo-controlled trial. Cerebrovasc Dis 2006;21(1/2):120-7
73. Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Sci 1995;56(9):637-60
74. Schabitz WR, Weber J, Takano K, et al. The effects of prolonged treatment with citicoline in temporary experimental focal ischemia. J Neurol Sci 1996;138(1/2):21-5
75. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE. A Phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001;57(9):1595-602
76. Cheng Y, Gidday JM, Yan Q, et al. Marked age-dependent neuroprotection by brain-derived neurotrophic factor against neonatal hypoxic-ischemic brain injury. Ann Neurol 1997;41(4):521-9
77. Holtzman DM, Sheldon RA, Jaffe W, et al. Nerve growth factor protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol 1996;39(1):114-22
78. Bogousslavsky J, Victor SJ, Salinas EO, et al. Fiblast (trafermin) in acute stroke: results of the European-Australian Phase II/III safety and efficacy trial. Cerebrovasc Dis 2002;14(3-4):239-51
79. Available from: http://clinicaltrials.gov/ct/show/NCT00229177
80. Belayev L, Liu Y, Zhao W, et al. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001;32(2):553-60
81. Zoellner H, Hofler M, Beckmann R, et al. Serum albumin is a specific inhibitor of apoptosis in human endothelial cells. J Cell Sci 1996;109(Pt 10):2571-80
82. Rodriguez De Turco EB, Belayev L, Liu Y, et al. Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin. J Neurochem 2002;83(3):515-24
83. Koch S, Concha M, Wazzan T, et al. High dose human serum albumin for the treatment of acute ischemic stroke: a safety study. Neurocrit Care 2004;1(3):335-41
84. Ginsberg MD, Hill MD, Palesch YY, et al. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke - I: physiological responses and safety results. Stroke 2006;37(8):2100-6
85. Ginsberg MD, Palesch YY, Hill MD. The ALIAS (ALbumin In Acute Stroke) Phase III randomized multicentre clinical trial: design and progress report. Biochem Soc Trans 2006;34(Pt 6):1323-6
86. Palesch YY, Hill MD, Ryckborst KJ, et al. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke - II: neurologic outcome and efficacy analysis. Stroke 2006;37(8):2107-14
87. Den Hertog H, Van Der Worp B, Van Gemert M, Dippel D. Therapeutic hypothermia in acute ischemic stroke. Expert Rev Neurother 2007;7(2):155-64
88. Brain attack: a look at stroke prevention and treatment. Available from: http://www.fda.gov/fdac/features/2005/205_stroke.html
89. Van Der Worp HB, Sena ES, Donnan GA, et al. Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain 2007;130(Pt 12):3063-74
90. Hemmen TM, Lyden PD. Induced hypothermia for acute stroke. Stroke 2007;38(2 Suppl):794-9
91. Guluma KZ, Oh H, Yu SW, et al. Effect of endovascular hypothermia on acute ischemic edema: morphometric analysis of the ICTuS Trial. Neurocrit Care 2008;8(1):42-7
92. Stroke therapy. booze, caffeine, and cooling? Discovery & Development - 31 October 2007. Available from: http://www.dddmag.com/ Stroke-Therapy-Booze-Caffeine-Cooling.aspx
93. Proctor PH, Tamborello LP. SAINT-I worked, but the neuroprotectant is not NXY-059. Stroke 2007;38(10):e109. (author reply e 110)
94. Zivin JA. Clinical trials of neuroprotective therapies. Stroke 2007;38(2 Suppl):791-3
95. Young AR, Ali C, Duretete A, Vivien D. Neuroprotection and stroke: time for a compromise. J Neurochem 2007;103(4):1302-9
96. Savitz SI, Fisher M. NXY-059 for the treatment of stroke. N Engl J Med 2007;357(21):2198 (author reply 2198-2199)
97. Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 2007;61(5):396-402
98. Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol 2007;205(1):20-5
99. Ginsberg MD. Response to letter by Fisher, et al. Stroke 2007;38(11):e128
100. Jeyaseelan K, Lim KY, Armugam A. MicroRNA expression in blood and brain of rats subjected to transient focal ischemia. Stroke 2008;39(3):959-66